CAJ | 학술논문

目的：分析442株大肠埃希菌临床感染分布及耐药性，为治疗大肠埃希菌感染及医院感染控制提供依据。方法对2013年临床送检的各类标本进行细菌培养及鉴定，采用微量肉汤稀释法（MIC）法检测大肠埃希菌对临床常用抗菌药物的敏感性，采用 WHONET5.5及 SPSS13.0软件对数据进行统计分析。结果442株大肠埃希菌主要分离自中段尿、分泌物，产 ESBLs大肠埃希菌检出率为61.3％。442株大肠埃希菌对青霉素类、头孢菌素类、氟喹诺酮类抗菌药物耐药率较高，对β-内酰胺／β-内酰胺酶抑制剂复合物敏感性较好，对碳青霉烯类抗菌药物敏感性最高。产 ESBLs 菌株对临床常用抗菌药物耐药率高于非产 ESBLs菌株。结论大肠埃希菌耐药性较为严峻，产 ESLBs 大肠埃希菌常表现出对多种不同类型抗菌药物耐药，治疗大肠埃希菌重症感染首选碳青霉烯类抗菌药物。
목적：분석442주대장애희균림상감염분포급내약성，위치료대장애희균감염급의원감염공제제공의거。방법대2013년림상송검적각류표본진행세균배양급감정，채용미량육탕희석법（MIC）법검측대장애희균대림상상용항균약물적민감성，채용 WHONET5.5급 SPSS13.0연건대수거진행통계분석。결과442주대장애희균주요분리자중단뇨、분비물，산 ESBLs대장애희균검출솔위61.3％。442주대장애희균대청매소류、두포균소류、불규낙동류항균약물내약솔교고，대β-내선알／β-내선알매억제제복합물민감성교호，대탄청매희류항균약물민감성최고。산 ESBLs 균주대림상상용항균약물내약솔고우비산 ESBLs균주。결론대장애희균내약성교위엄준，산 ESLBs 대장애희균상표현출대다충불동류형항균약물내약，치료대장애희균중증감염수선탄청매희류항균약물。
Objective To analyze the clinical infection distribution and drug resistance status of 442 strains of Escherichia coli to provide the basise for the treatment of Escherichia coli infection and the control of nosocomial infection.Methods The clinically submitted various kinds of specimens during 2013 were performed the bacterial culture and identification.The susceptibility of Escherichia coli to commonly used bacterial drugs were detected by adopting the MIC method.The data were analyzed by WHO-NET V5.5 and SPSS V13.0 softwares.Results 442 strains of Escherichia coli were isolated from the middle urine and secretion. The detection rate of ESBLs-producing Escherichia coli was 61.3%.442 strains of Escherichia coli had the high resistance to peni-cillins,cephalosporins and fluoroquinolones,better sensitivity toβ-lactam/β-lactamase inhibitor compounds and highest sensitivity to carbapenems.ESBLs-producing Escherichia coli had the higher resistance to commonly used antibacterial drugs than non-ESBLs-producing Escherichia coli .Conclusion The drug resistance of Escherichia coli is severe.ESBLs-producing Escherichia coli are u-sually resistant to many different types of antimicrobial drugs.Carbapenems are the first choice to treatment of severe infections of Escherichia coli .